These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 10975381)

  • 1. Soluble HLA class I and Fas ligand molecules in blood components and their role in the immunomodulatory effects of blood transfusions.
    Ghio M; Contini P; Mazzei C; Brenci S; Filaci G; Indiveri F; Puppo F
    Leuk Lymphoma; 2000 Sep; 39(1-2):29-36. PubMed ID: 10975381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble HLA class I, HLA class II, and Fas ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusions.
    Ghio M; Contini P; Mazzei C; Brenci S; Barberis G; Filaci G; Indiveri F; Puppo F
    Blood; 1999 Mar; 93(5):1770-7. PubMed ID: 10029607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The immunomodulatory effect of blood transfusions and intravenous immunoglobulins: the role of the soluble molecules of the Class-I major histocompatibility complex and of the Fas ligand].
    Ghio M; Contini P; Puppo F; Indiveri F
    Ann Ital Med Int; 2000; 15(1):70-4. PubMed ID: 10842894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomodulatory effects of blood transfusions: the synergic role of soluble HLA Class I free heavy-chain molecules detectable in blood components.
    Ghio M; Contini P; Ubezio G; Mazzei C; Puppo F; Indiveri F
    Transfusion; 2008 Aug; 48(8):1591-7. PubMed ID: 18466172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble HLA class I molecules/CD8 ligation trigger apoptosis of CD8+ cells by Fas/Fas-ligand interaction.
    Puppo F; Contini P; Ghio M; Indiveri F
    ScientificWorldJournal; 2002 Feb; 2():421-3. PubMed ID: 12806026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro immunosuppressive activity of soluble HLA class I and Fas ligand molecules: do they play a role in autologous blood transfusion?
    Ghio M; Contini P; Mazzei C; Merlo A; Filaci G; Setti M; Indiveri F; Puppo F
    Transfusion; 2001 Aug; 41(8):988-96. PubMed ID: 11493729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation.
    Contini P; Ghio M; Poggi A; Filaci G; Indiveri F; Ferrone S; Puppo F
    Eur J Immunol; 2003 Jan; 33(1):125-34. PubMed ID: 12594841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble HLA class I/CD8 ligation triggers apoptosis in EBV-specific CD8+ cytotoxic T lymphocytes by Fas/Fas-ligand interaction.
    Contini P; Ghio M; Merlo A; Brenci S; Filaci G; Indiveri F; Puppo F
    Hum Immunol; 2000 Dec; 61(12):1347-51. PubMed ID: 11163092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune homeostasis requires several biologic factors including glucocorticoid hormones.
    Cancedda C; Filaci G; Puppo F; Ghio M; Contini P; Indiveri F
    Ann N Y Acad Sci; 2002 Jun; 966():49-63. PubMed ID: 12114258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutting edge: soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8.
    Fournel S; Aguerre-Girr M; Huc X; Lenfant F; Alam A; Toubert A; Bensussan A; Le Bouteiller P
    J Immunol; 2000 Jun; 164(12):6100-4. PubMed ID: 10843658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. sHLA-I contaminating molecules as novel mechanism of ex vivo/in vitro transcriptional and posttranscriptional modulation of transforming growth factor-beta in CD8+ T lymphocytes and neutrophils after intravenous immunoglobulin treatment.
    Ghio M; Contini P; Negrini S; Proietti M; Gonella R; Ubezio G; Ottonello L; Indiveri F
    Transfusion; 2010 Mar; 50(3):547-55. PubMed ID: 19906035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bio-modulators in platelet-rich plasma: a comparison of the amounts in products from healthy donors and patients produced with three different techniques.
    Ubezio G; Ghio M; Contini P; Bertorello R; Marino G; Tomasini A; Tripodi G
    Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s214-20. PubMed ID: 23399357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of clotting factors concentrates on lymphocyte and neutrophil function in vitro.
    Ghio M; Contini P; Ottonello L; Arduino N; Gringeri A; Indiveri F; Dallegri F; Puppo F
    Thromb Haemost; 2003 Feb; 89(2):365-73. PubMed ID: 12574818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
    Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
    J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positive and negative consequences of soluble Fas ligand produced by an antigen-specific CD4(+) T cell response in human carcinoma immune interactions.
    Bergmann-Leitner ES; Abrams SI
    Cell Immunol; 2001 Apr; 209(1):49-62. PubMed ID: 11414736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonleukoreduced red blood cell transfusion induces a sustained inhibition of neutrophil chemotaxis by stimulating in vivo production of transforming growth factor-beta1 by neutrophils: role of the immunoglobulinlike transcript 1, sFasL, and sHLA-I.
    Ottonello L; Ghio M; Contini P; Bertolotto M; Bianchi G; Montecucco F; Colonna M; Mazzei C; Dallegri F; Indiveri F
    Transfusion; 2007 Aug; 47(8):1395-404. PubMed ID: 17655583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of a combination of soluble Fas and soluble Fas ligand in the serum of patients with Ta bladder cancer.
    Mizutani Y; Yoshida O; Ukimura O; Kawauchi A; Bonavida B; Miki T
    Cancer Biother Radiopharm; 2002 Oct; 17(5):563-7. PubMed ID: 12470426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ex vivo soluble fas ligand treatment of donor cells to selectively reduce murine acute graft versus host disease.
    Georgantas RW; Bohana-Kashtan O; Civin CI
    Transplantation; 2006 Aug; 82(4):471-8. PubMed ID: 16926590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression of Fas receptor and soluble Fas ligand (sFasL) concentration in acute leukemia].
    Urbaniak-Kujda D; Jaźwiec B; Tomaszewska-Toporska B; Wołowiec D; Kapelko-Słowik K; Kuliczkowski K
    Pol Arch Med Wewn; 2002 Sep; 108(3):873-8. PubMed ID: 12600184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variations in the serum concentrations of soluble Fas and soluble Fas ligand in Vietnamese patients infected with hepatitis B virus.
    Song le H; Binh VQ; Duy DN; Bock TC; Kremsner PG; Luty AJ; Mavoungou E
    J Med Virol; 2004 Jun; 73(2):244-9. PubMed ID: 15122799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.